• A Discussion with Gil Aharon of Rosalind Advisors: Biotech Investing, Verona Pharma & Delcath Systems

  • Dec 13 2021
  • Length: 1 hr and 7 mins
  • Podcast

A Discussion with Gil Aharon of Rosalind Advisors: Biotech Investing, Verona Pharma & Delcath Systems

Listen for free

View show details

  • Summary

  • An interview with Gil Aharon of Rosalind Advisors, where we discuss his perspective on the macro biotech market. Having run a dedicated life science fund for >10 years, Gil puts today's difficult biotech market into historical context and offers his opinion on why investors should be optimistic for the future. During the interview, we also discuss two of Gil's favorite smaller health care names, Verona Pharma and Delcath Systems.

    Companies discussed during the podcast;

    • Verona Pharma plc (Nasdaq: VRNA)
    • Delcath Systems, Inc (Nasdaq: DCTH)
    • Immunogen Inc (Nasdaq: IMGN)

    Gil Aharon, who is a director of Delcath Systems, Inc. (“Delcath”) appeared on this episode of the podcast. Listeners are urged to review Delcath’s SEC filings and cautioned not to place undue reliance on any forward-looking statements. Delcath undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.
    Show More Show Less
Show More Show Less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about A Discussion with Gil Aharon of Rosalind Advisors: Biotech Investing, Verona Pharma & Delcath Systems

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.co.uk reviews

Amazon reviews
No Reviews are Available